Escherichia coli Infections – Pipeline Review H2 2017, analysis by stage of development and overview of key players involved (ContraFect Corp, Debiopharm International SA, Emergent BioSolutions)

A new independent 171 page research with title ‘Escherichia coli Infections – Pipeline Review, H2 2017’  guarantees you will remain better informed than your competition. The study covers geographic analysis that includes important players/vendors such as ContraFect Corp, Debiopharm International SA, Emergent BioSolutions , F. Hoffmann-La Roche etc With n-number of tables and figures examining the Escherichia coli Infections, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022

Request a sample report @ https://www.htfmarketreport.com/sample-report/795639-escherichia-coli-infections-pipeline-review-1

Escherichia coli Infections – Pipeline Review, H2 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections – PipelineReview, H2 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.
Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 1, 31 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 7 and 14 molecules, respectively.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Place a Purchase Order for this Market Report (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=795639

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report
Adenium Biotech ApS
AstraZeneca Plc
Atterx Biotherapeutics Inc
AvidBiotics Corp
ContraFect Corp
Debiopharm International SA
Emergent BioSolutions Inc
F. Hoffmann-La Roche Ltd
Hsiri Therapeutics LLC
ImmunoClin Corp
Immuron Ltd
Innovation Pharmaceuticals Inc
Johnson & Johnson
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Nabriva Therapeutics plc
Navigen Inc
Nosopharm SAS
Novabiotics Ltd
Paratek Pharmaceuticals Inc
Phico Therapeutics Ltd
PTC Therapeutics Inc
Recce Ltd
Sealife PHARMA GMBH
Syntiron LLC
Tetraphase Pharmaceuticals Inc
Venus Medicine Research Center

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/795639-escherichia-coli-infections-pipeline-review-1

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Escherichia coli Infections – Overview 8
Escherichia coli Infections – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 16
Products under Development by Universities/Institutes 19
Escherichia coli Infections – Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Escherichia coli Infections – Companies Involved in Therapeutics Development 31
Adenium Biotech ApS 31
AstraZeneca Plc 31
Atterx Biotherapeutics Inc 31
AvidBiotics Corp 32
ContraFect Corp 32
Debiopharm International SA 33
Emergent BioSolutions Inc 33
F. Hoffmann-La Roche Ltd 34
Hsiri Therapeutics LLC 34
ImmunoClin Corp 35
Immuron Ltd 35
Innovation Pharmaceuticals Inc 35
Johnson & Johnson 36
Kyorin Pharmaceutical Co Ltd 36
Melinta Therapeutics Inc 37
Merck & Co Inc 37
Microbiotix Inc 38
Nabriva Therapeutics plc 38
Navigen Inc 39
Nosopharm SAS 39
Novabiotics Ltd 39
Paratek Pharmaceuticals Inc 40
Phico Therapeutics Ltd 40
PTC Therapeutics Inc 41
Recce Ltd 41
Sealife PHARMA GMBH 42
Syntiron LLC 42
Tetraphase Pharmaceuticals Inc 42
Venus Medicine Research Center 43

….Continued

Browse Complete 171 page Detailed report & its TOC @ https://www.htfmarketreport.com/reports/795639-escherichia-coli-infections-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
sales@htfmarketreport.com
Ph: +1 (206) 317 1218
Connect with us on:
https://www.linkedin.com/company/13388569/
https://twitter.com/htfmarketreport